www.fdanews.com/articles/188564-baxters-altapore-bioactive-bone-graft-receives-extended-510k-clearance
Baxter’s Altapore Bioactive Bone Graft Receives Extended 510(k) Clearance
September 26, 2018
Baxter received an extended 510(k) clearance for its Altapore bioactive bone graft, a bioactive and osteoconductive bone graft substitute.
The additional clearance allows the bone graft to be used as an autograft extender in posterolateral spinal fusion.
The bone graft received previous 510(k) clearance for use in orthopedic surgery in the pelvis and the extremities.